AB 1763: Health care coverage: colorectal cancer: screening and testing.
- Session Year: 2015-2016
- House: Assembly
- Latest Version Date: 2016-08-25
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires individual and group health care service plan contracts and health insurance policies to provide coverage for all generally medically accepted cancer screening tests and requires those contracts and policies to also provide coverage for the treatment of breast cancer. Existing law requires an individual or small group health care service plan contract or insurance policy issued, amended, or renewed on or after January 1, 2014, to, at a minimum, include coverage for essential health benefits, which include preventive services, pursuant to the federal Patient Protection and Affordable Care Act.
This bill would require a health care service plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without cost sharing for colorectal cancer screening examinations and laboratory tests, as specified. The bill would require the coverage to include additional colorectal cancer screening examinations as listed by the United States Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program if the individual is at high risk for colorectal cancer. The bill would prohibit a health care service plan contract or a health insurance policy from imposing cost sharing on an individual who is between 50 and 75 years of age for colonoscopies conducted for specified purposes. The bill would also provide that it does not require a plan or insurer to provide benefits for items or services delivered by an out-of-network provider and does not preclude a plan or insurer from imposing cost-sharing requirements for items or services that are delivered by an out-of-network provider. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires individual and group health care service plan contracts and health insurance policies to provide coverage for all generally medically accepted cancer screening tests and requires those contracts and policies to also provide coverage for the treatment of breast cancer. Existing law requires an individual or small group health care service plan contract or insurance policy issued, amended, or renewed on or after January 1, 2014, to, at a minimum, include coverage for essential health benefits, which include preventive services, pursuant to the federal Patient Protection and Affordable Care Act.
This bill would require a health care service plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without cost sharing for colorectal cancer screening examinations and laboratory tests, as specified. The bill would require the coverage to include additional colorectal cancer screening examinations as listed by the United States Preventative Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program if the individual is at high risk for colorectal cancer. The bill would prohibit a health care service plan contract or a health insurance policy from imposing cost sharing on an individual who is between 50 and 75 years of age for colonoscopies conducted for specified purposes. The bill would also provide that it does not require a plan or insurer to provide benefits for items or services delivered by an out-of-network provider and does not preclude a plan or insurer from imposing cost-sharing requirements for items or services that are delivered by an out-of-network provider. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires individual and group health care service plan contracts and health insurance policies to provide coverage for all generally medically accepted cancer screening tests and requires those contracts and policies to also provide coverage for the treatment of breast cancer. Existing law requires an individual or small group health care service plan contract or insurance policy issued, amended, or renewed on or after January 1, 2014, to, at a minimum, include coverage for essential health benefits, which include preventive services, pursuant to the federal Patient Protection and Affordable Care Act.
This bill would require a health care service plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without cost sharing for colorectal cancer screening examinations and laboratory tests, as specified. The bill would require the coverage to include additional colorectal cancer screening examinations and laboratory tests recommended by the health care provider, as listed by the United States Preventative Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program if the individual is at high risk for colorectal cancer, as determined by the health care provider. cancer. The bill would prohibit a health care service plan contract or a health insurance policy from imposing cost sharing on an individual who is 50 between 50 and 75 years of age or older for colonoscopies conducted for specified purposes. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires individual and group health care service plan contracts and health insurance policies to provide coverage for all generally medically accepted cancer screening tests and requires those contracts and policies to also provide coverage for the treatment of breast cancer. Existing law requires an individual or small group health care service plan contract or insurance policy issued, amended, or renewed on or after January 1, 2014, to, at a minimum, include coverage for essential health benefits, which include preventive services, pursuant to the federal Patient Protection and Affordable Care Act.
This bill would require a health care service plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without cost sharing for colorectal cancer screening examinations and laboratory tests, as specified. The bill would require the coverage to include additional colorectal cancer screening examinations and laboratory tests recommended by the treating physician health care provider, if the individual is at high risk for colorectal cancer. cancer, as determined by the health care provider. The bill would prohibit a health care service plan contract or a health insurance policy from imposing cost sharing on this coverage for an individual who is 50 years of age or older. older for colonoscopies conducted for specified purposes. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care and makes a willful violation of the act a crime. Existing law also provides for the regulation of health insurers by the Department of Insurance. Existing law requires individual and group health care service plan contracts and health insurance policies to provide coverage for all generally medically accepted cancer screening tests and requires those contracts and policies to also provide coverage for the treatment of breast cancer. Existing law requires an individual or small group health care service plan contract or insurance policy issued, amended, or renewed on or after January 1, 2014, to, at a minimum, include coverage for essential health benefits, which include preventive services, pursuant to the federal Patient Protection and Affordable Care Act.
This bill would require a health care service plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage for colorectal cancer screening examinations and laboratory tests, as specified. The bill would require the coverage to include additional colorectal cancer screening examinations and laboratory tests recommended by the treating physician if the individual is at high risk for colorectal cancer. The bill would prohibit a health care service plan contract or a health insurance policy from imposing cost sharing on this coverage for an individual who is 50 years of age or older. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)Every health care service plan contract, except a specialized health care service plan contract, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an enrollee is at high risk for colorectal cancer, the coverage required by this subdivision shall include additional colorectal cancer screening examinations as listed by the United States Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an enrollee who is between 50 and 75 years of age, a health care service plan contract shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(c)Nothing in this section requires a plan that has a network of providers to provide benefits for items or services described in this section that are delivered by an out-of-network provider or precludes a plan that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
SEC. 2.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)Every health insurance policy, except a specialized health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an insured is at high risk for colorectal cancer, the coverage required by this subdivision shall include additional colorectal cancer screening examinations as listed by the United States Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an insured who is between 50 and 75 years of age, a health insurance policy shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(c)Nothing in this section requires an insurer that has a network of providers to provide benefits for items or services described in this section that are delivered by an out-of-network provider or precludes an insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Every health care service plan contract, except a specialized health care service plan contract, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an enrollee is at high risk for colorectal cancer, the coverage required by this subdivision shall include additional colorectal cancer screening examinations as listed by the United States Preventative Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an enrollee who is between 50 and 75 years of age, a health care service plan contract shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(c)Nothing in this section requires a plan that has a network of providers to provide benefits for items or services described in this section that are delivered by an out-of-network provider or precludes a plan that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
SEC. 2.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)Every health insurance policy, except a specialized health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an insured is at high risk for colorectal cancer, the coverage required by this subdivision shall include additional colorectal cancer screening examinations as listed by the United States Preventative Preventive Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an insured who is between 50 and 75 years of age, a health insurance policy shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(c)Nothing in this section requires an insurer that has a network of providers to provide benefits for items or services described in this section that are delivered by an out-of-network provider or precludes an insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Every health care service plan contract, except a specialized health care service plan contract, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an enrollee is at high risk for colorectal cancer as determined by the enrollees health care provider, cancer, the coverage required by this subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the enrollees health care provider. as listed by the United States Preventative Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an enrollee who is 50 years of age or older, between 50 and 75 years of age, a health care service plan contract shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
SEC. 2.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)Every health insurance policy, except a specialized health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. If an insured is at high risk for colorectal cancer as determined by the insureds health care provider, cancer, the coverage required by this subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the insureds health care provider. as listed by the United States Preventative Services Task Force as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
(b)For an insured who is 50 years of age or older, between 50 and 75 years of age, a health insurance policy shall not impose cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Every health care service plan contract, except a specialized health care service plan contract, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. The coverage shall include, at a minimum, all of the following:
(1)High sensitivity fecal occult blood tests (FOBT).
(2)Flexible sigmoidoscopy with high sensitivity FOBT.
(3)Colonoscopies, including the removal of polyps during a screening procedure.
(b)(1)If risk. If an enrollee is at high risk for colorectal cancer, cancer as determined by the enrollees health care provider, the coverage required by subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the treating physician. enrollees health care provider.
(2)For purposes of this subdivision, an individual is at high risk for colorectal cancer if the individual has any of the following:
(A)A family medical history of colorectal cancer.
(B)A prior occurrence of cancer or precursor neoplastic polyps.
(C)A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohns disease, or ulcerative colitis.
(D)Other predisposing factors.
(c)
(b)For an enrollee who is 50 years of age or older, a health care service plan contract shall not impose cost sharing on either of the following: colonoscopies, including the removal of polyps, when either of the following applies:
(1)The coverage required by this section.
(2)Colonoscopies, including the removal of polyps during a screening procedure, if the enrollee has a positive result on any fecal test assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(d)Paragraph (3) of subdivision (a) shall not apply to a high deductible health plan, as described in Section 223 of Title 26 of the United States Code.
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
SEC. 2.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)Every health insurance policy, except a specialized health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage without cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. The coverage shall include, at a minimum, all of the following:
(1)High sensitivity fecal occult blood tests (FOBT).
(2)Flexible sigmoidoscopy with high sensitivity FOBT.
(3)Colonoscopies, including the removal of polyps during a screening procedure.
(b)(1)If risk. If an insured is at high risk for colorectal cancer, cancer as determined by the insureds health care provider, the coverage required by subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the treating physician. insureds health care provider.
(2)For purposes of this subdivision, an individual is at high risk for colorectal cancer if the individual has any of the following:
(A)A family medical history of colorectal cancer.
(B)A prior occurrence of cancer or precursor neoplastic polyps.
(C)A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohns disease, or ulcerative colitis.
(D)Other predisposing factors.
(c)
(b)For an insured who is 50 years of age or older, a health insurance policy shall not impose cost sharing on either of the following: colonoscopies, including the removal of polyps, when either of the following applies:
(1)The coverage required by this section.
(2)Colonoscopies, including the removal of polyps during a screening procedure, if the insured has a positive result on any fecal test assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(d)Paragraph (3) of subdivision (a) shall not apply to a high deductible health plan, as described in Section 223 of Title 26 of the United States Code.
(1)The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure.
(2)The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Every health care service plan contract, except a specialized health care service plan contract, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. The coverage shall include, at a minimum, all of the following:
(1)High sensitivity fecal occult blood tests (FOBT).
(2)Flexible sigmoidoscopy with high sensitivity FOBT.
(3)Colonoscopies, including the removal of polyps during a screening procedure.
(b)(1)If an enrollee is at high risk for colorectal cancer, the coverage required by subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the treating physician.
(2)For purposes of this subdivision, an individual is at high risk for colorectal cancer if the individual has any of the following:
(A)A family medical history of colorectal cancer.
(B)A prior occurrence of cancer or precursor neoplastic polyps.
(C)A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohns disease, or ulcerative colitis.
(D)Other predisposing factors.
(c)For an enrollee who is 50 years of age or older, a health care service plan contract shall not impose cost sharing on either of the following:
(1)The coverage required by this section.
(2)Colonoscopies, including the removal of polyps during a screening procedure, if the enrollee has a positive result on any fecal test assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(d)Paragraph (3) of subdivision (a) shall not apply to a high deductible health plan, as described in Section 223 of Title 26 of the United States Code.
SEC. 2.Section 10123.205 is added to the Insurance Code, to read:10123.205.(a)Every health insurance policy, except a specialized health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, shall provide coverage for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the United States Preventive Services Task Force for individuals at average risk. The coverage shall include, at a minimum, all of the following:
(1)High sensitivity fecal occult blood tests (FOBT).
(2)Flexible sigmoidoscopy with high sensitivity FOBT.
(3)Colonoscopies, including the removal of polyps during a screening procedure.
(b)(1)If an insured is at high risk for colorectal cancer, the coverage required by subdivision (a) shall include additional colorectal cancer screening examinations and laboratory tests as recommended by the treating physician.
(2)For purposes of this subdivision, an individual is at high risk for colorectal cancer if the individual has any of the following:
(A)A family medical history of colorectal cancer.
(B)A prior occurrence of cancer or precursor neoplastic polyps.
(C)A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohns disease, or ulcerative colitis.
(D)Other predisposing factors.
(c)For an insured who is 50 years of age or older, a health insurance policy shall not impose cost sharing on either of the following:
(1)The coverage required by this section.
(2)Colonoscopies, including the removal of polyps during a screening procedure, if the insured has a positive result on any fecal test assigned either a grade of A or a grade of B by the United States Preventive Services Task Force.
(d)Paragraph (3) of subdivision (a) shall not apply to a high deductible health plan, as described in Section 223 of Title 26 of the United States Code.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Aug 30, 2016 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 23, 2016 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 64. Noes 12. Page 6161.). |
| Aug 23, 2016 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 19, 2016 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 21 pursuant to Assembly Rule 77. |
| Aug 18, 2016 | Read third time. Passed. Ordered to the Assembly. (Ayes 24. Noes 12. Page 5135.). |
| Aug 18, 2016 | Read third time. Passed. Ordered to the Assembly. (Ayes 24. Noes 12.). |
| Aug 18, 2016 | Read third time. Passed. Ordered to the Assembly. |
| Aug 15, 2016 | Read second time. Ordered to third reading. |
| Aug 11, 2016 | From committee: Do pass. (Ayes 5. Noes 2.) (August 11). |
| Aug 1, 2016 | In committee: Referred to APPR. suspense file. |
| Jun 27, 2016 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 23, 2016 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 7. Noes 1.) (June 22). |
| Jun 15, 2016 | Referred to Com. on HEALTH. |
| Jun 6, 2016 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jun 2, 2016 | Read third time. Passed. Ordered to the Senate. (Ayes 67. Noes 5. Page 5217.) |
| Jun 2, 2016 | Read third time. Passed. Ordered to the Senate. (Ayes 67. Noes 5.) |
| Jun 2, 2016 | Read third time. Passed. Ordered to the Senate. |
| Jun 1, 2016 | Read second time. Ordered to third reading. |
| May 31, 2016 | Read second time and amended. Ordered returned to second reading. |
| May 27, 2016 | From committee: Amend, and do pass as amended. (Ayes 14. Noes 3.) (May 27). |
| May 4, 2016 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 28, 2016 | Re-referred to Com. on APPR. |
| Apr 27, 2016 | Read second time and amended. |
| Apr 26, 2016 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 14. Noes 0.) (April 19). |
| Feb 18, 2016 | Referred to Com. on HEALTH. |
| Feb 4, 2016 | From printer. May be heard in committee March 5. |
| Feb 3, 2016 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 23, 2016 | AB 1763 GIPSON Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 18, 2016 | Assembly 3rd Reading AB1763 Gipson By Pan | Senate Floor |
Passed |
|
| Aug 11, 2016 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 1, 2016 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 22, 2016 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| Jun 2, 2016 | AB 1763 GIPSON Assembly Third Reading | Assembly Floor |
Passed |
|
| May 27, 2016 | Do pass as amended. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 19, 2016 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
GOVERNOR'S VETO
GV Bill Id:AB 1763
Author:(Gipson)
As Enrolled Ver:August 30, 2016
2/3 vote
ASSEMBLY: | 67-5 | (June 2, 2016) | SENATE: | 24-12 | (August 18, 2016) |
ASSEMBLY: | 64-12 | (August 23, 2016) |
|
|
Original Committee Reference: HEALTH
SUMMARY: Requires health care service plan (health plan) and health insurance coverage without cost sharing for specified colorectal cancer screening examinations and laboratory tests for individuals at average risk, and requires coverage for additional colorectal cancer screening examinations without cost-sharing for individuals at high risk, as specified. Prohibits the imposition of cost sharing on colonoscopies, including the removal of polyps, for an enrollee who is between 50 and 75 years of age and has received a positive test, as specified.
The Senate amendments add language specifying that this bill does not require a health plan or insurer with a network of providers to provide benefits for out-of-network services nor does it preclude a health plan or insurer with a network of providers from imposing cost-sharing requirements for out-of-network provider services.
FISCAL EFFECT: According to the Senate Appropriations Committee:
- No fiscal impact on the Medi-Cal program is anticipated, as program beneficiaries are not subject to cost sharing.
- Increased costs of $1.3 million per year to CalPERS (California Public Employees' Retirement System), due to increased utilization of screening tests (various funds). According to an analysis of a prior version of this bill by the California Health Benefits Review Program (CHBRP), prohibiting cost sharing for specified screening will modestly increase utilization of screening examinations. Overall, CHBRP projects that about 2,500 additional individuals per year will receive colorectal screening exams due to the elimination of cost sharing. The proportional impact of that increased utilization on the CalPERS system is $1.3 million. According to CHBRP, subsequent amendments to this bill since that analysis was prepared will not substantially change the projected costs.
- No state cost to subsidize health care coverage through Covered California is anticipated. Under federal law, any new mandated health benefit that exceeds the benefits in the states essential health benefits benchmark plan would be a state responsibility. In other words, to the extent that the state imposes a new benefit mandate that exceeds the essential health benefits benchmark, the state would be responsible for paying for the cost to subsidize that benefit for those individuals who receive subsidized coverage through Covered California. Because this bill does not mandate a new benefit, but only change the terms of an existing benefit, this bill is not expected to result in the state being responsible for subsidizing coverage.
- One-time costs of about $90,000 over the first two years and ongoing costs of $25,000 per year for reviews of insurance plan compliance by the Department of Insurance (CDI Insurance Fund).
- Ongoing costs of less than $50,000 per year for review of health plan compliance by the Department of Managed Health Care (DMHC Managed Care Fund).
COMMENTS: According to the author, stool blood tests are an important colorectal cancer screening option. Availability is better than for colonoscopy, the cost is lower, and they offer the opportunity to increase the overall screening rate which would reduce incidence and mortality. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy. Some prefer a stool blood test because the procedure is simpler, there is lower risk of complications and it is less invasive. Screening with stool blood tests has been shown to decrease incidence and mortality in randomized controlled trials, and years of life saved are essentially the same as with colonoscopy screening. However, the benefits of stool blood tests as a strategy to reach more Californians, especially in communities with lower access to colonoscopy services are not realized when there is a cost to patients. A co-pay or cost-sharing can be a barrier, preventing some individuals with positive stool blood tests from getting a follow up colonoscopy to complete the colorectal cancer screening process, defeating the purpose of screening. A policy that removes the cost to patients will make stool blood tests a more viable screening option and will reduce costs to payers.
Patient Protection and Affordable Care Act (ACA) Preventive Services Mandate. The ACA requires coverage for and elimination of cost-sharing on certain recommended preventive health services, for policies renewing on or after September 23, 2010, based on guidelines from the United States Preventive Services Task Force (USPSTF). There are 15 covered preventive services for adults which include one-time screening for abdominal aortic aneurysm, screening and counseling for alcohol misuse, aspirin, blood pressure screening, cholesterol screening, depression screening, screening for Type 2 Diabetes, diet counseling, HIV screening, immunizations, obesity screening and counseling, prevention counseling for sexually transmitted infection, screening and cessation interventions for tobacco use, and colorectal cancer screening for adults over 50.
Colorectal Cancer Screening. According to the National Cancer Institute, colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal cancer is the second leading cause of death from cancer in the United States. For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years. A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer. The final USPSTF recommendation for colorectal cancer screening recommends screening with one of several approved methodologies for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patients overall health and prior screening history. The screening modalities and intervals are fecal occult blood test, which has received an A or B recommendation from the USPSTF and Fecal immunochemical test, which is recommended in the 2016 draft updated guidelines. Both tests are suggested annually to detect cancer. A flexible sigmoidoscopy is recommended every five years to detect polyps and cancer and has received an A or B recommendation from the USPSTF. A colonoscopy is recommended every 10 years to detect polyps and cancer and has received an A or B recommendation. It is also recommended that a colonoscopy should be performed if test results are positive.
I am returning Assembly Bill 1763 without my signature.
This bill imposes a no cost sharing mandate on health plans and insurance policies for colorectal cancer screening services that exceeds the requirements of the federal Affordable Care Act.
I understand the importance of preventative health care services, and in particular, screening for various types of cancer. I believe, however, the cost sharing rules for these services as set in the Affordable Care Act are sufficient. Moreover, creating a no cost sharing rule for colorectal cancer sets it apart from all other cancers and contributes to increasing everyone's health care costs.
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0005102
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1763
Author:(Gipson)
As Amended Ver:June 27, 2016
Majority vote
ASSEMBLY: | 67-5 | (June 2, 2016) | SENATE: | 24-12 | (August 18, 2016) |
Original Committee Reference: HEALTH
SUMMARY: Requires health care service plan (health plan) and health insurance coverage without cost sharing for specified colorectal cancer screening examinations and laboratory tests for individuals at average risk, and requires coverage for additional colorectal cancer screening examinations without cost-sharing for individuals at high risk, as specified. Prohibits the imposition of cost sharing on colonoscopies, including the removal of polyps, for an enrollee who is between 50 and 75 years of age and has received a positive test, as specified.
The Senate amendments add language specifying that this bill does not require a health plan or insurer with a network of providers to provide benefits for out-of-network services nor does it preclude a health plan or insurer with a network of providers from imposing cost-sharing requirements for out-of-network provider services.
FISCAL EFFECT: According to the Senate Appropriations Committee:
- No fiscal impact on the Medi-Cal program is anticipated, as program beneficiaries are not subject to cost sharing.
- Increased costs of $1.3 million per year to CalPERS, due to increased utilization of screening tests (various funds). According to an analysis of a prior version of this bill by the California Health Benefits Review Program (CHBRP), prohibiting cost sharing for specified screening will modestly increase utilization of screening examinations. Overall, CHBRP projects that about 2,500 additional individuals per year will receive colorectal screening exams due to the elimination of cost sharing. The proportional impact of that increased utilization on the CalPERS system is $1.3 million. According to CHBRP, subsequent amendments to this bill since that analysis was prepared will not substantially change the projected costs.
- No state cost to subsidize health care coverage through Covered California is anticipated. Under federal law, any new mandated health benefit that exceeds the benefits in the states essential health benefits benchmark plan would be a state responsibility. In other words, to the extent that the state imposes a new benefit mandate that exceeds the essential health benefits benchmark, the state would be responsible for paying for the cost to subsidize that benefit for those individuals who receive subsidized coverage through Covered California. Because this bill does not mandate a new benefit, but only change the terms of an existing benefit, this bill is not expected to result in the state being responsible for subsidizing coverage.
- One-time costs of about $90,000 over the first two years and ongoing costs of $25,000 per year for reviews of insurance plan compliance by the Department of Insurance (CDI Insurance Fund).
- Ongoing costs of less than $50,000 per year for review of health plan compliance by the Department of Managed Health Care (DMHC Managed Care Fund).
COMMENTS: According to the author, stool blood tests are an important colorectal cancer screening option. Availability is better than for colonoscopy, the cost is lower, and they offer the opportunity to increase the overall screening rate which would reduce incidence and mortality. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy. Some prefer a stool blood test because the procedure is simpler, there is lower risk of complications and it is less invasive. Screening with stool blood tests has been shown to decrease incidence and mortality in randomized controlled trials, and years of life saved are essentially the same as with colonoscopy screening. However, the benefits of stool blood tests as a strategy to reach more Californians, especially in communities with lower access to colonoscopy services are not realized when there is a cost to patients. A co-pay or cost-sharing can be a barrier, preventing some individuals with positive stool blood tests from getting a follow up colonoscopy to complete the colorectal cancer screening process, defeating the purpose of screening. A policy that removes the cost to patients will make stool blood tests a more viable screening option and will reduce costs to payers.
Patient Protection and Affordable Care Act (ACA) Preventive Services Mandate. The ACA requires coverage for and elimination of cost-sharing on certain recommended preventive health services, for policies renewing on or after September 23, 2010, based on guidelines from the United States Preventive Services Task Force (USPSTF). There are 15 covered preventive services for adults which include one-time screening for abdominal aortic aneurysm, screening and counseling for alcohol misuse, aspirin, blood pressure screening, cholesterol screening, depression screening, screening for Type 2 Diabetes, diet counseling, HIV screening, immunizations, obesity screening and counseling, prevention counseling for sexually transmitted infection, screening and cessation interventions for tobacco use, and colorectal cancer screening for adults over 50.
Colorectal Cancer Screening. According to the National Cancer Institute, colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal cancer is the second leading cause of death from cancer in the United States. For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years. A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer. The final USPSTF recommendation for colorectal cancer screening recommends screening with one of several approved methodologies for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patients overall health and prior screening history. The screening modalities and intervals are fecal occult blood test (FOBT), which has received an A or B recommendation from the USPSTF and Fecal immunochemical test (FIT), which is recommended in the 2016 draft updated guidelines. Both tests are suggested annually to detect cancer. A flexible sigmoidoscopy is recommended every five years to detect polyps and cancer and has received an A or B recommendation from the USPSTF. A colonoscopy is recommended every 10 years to detect polyps and cancer and has received an A or B recommendation. It is also recommended that a colonoscopy should be performed if test results are positive.
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0004119
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1763 |
THIRD READING
Bill No: AB 1763
Amended: 6/27/16 in Senate
SENATE HEALTH COMMITTEE: 7-1, 6/22/16
AYES: Hernandez, Hall, Mitchell, Monning, Pan, Roth, Wolk
NOES: Nielsen
NO VOTE RECORDED: Nguyen
SENATE APPROPRIATIONS COMMITTEE: 5-2, 8/11/16
AYES: Lara, Beall, Hill, McGuire, Mendoza
NOES: Bates, Nielsen
ASSEMBLY FLOOR: 67-5, 6/2/16 - See last page for vote
SUBJECT: Health care coverage: colorectal cancer: screening and testing
SOURCE: American Cancer Society Cancer Action Network
California Colorectal Cancer Coalition
DIGEST: This bill requires health plan and health insurance coverage without cost sharing for specified colorectal cancer screening examinations and laboratory tests for individuals at average risk, and requires coverage for additional colorectal cancer screening examinations without cost-sharing for individuals at high risk, as specified. Prohibits the imposition of cost sharing on colonoscopies, including the removal of polyps, for an enrollee who is between 50 and 75 years of age and has received a positive test, as specified.
Existing federal law:
- Requires, pursuant to the Affordable Care Act (ACA), coverage of 10 essential health benefits and places limits on cost sharing.
- Requires, pursuant to Section 2713 of the Public Health Services Act, as added by the ACA, the preventive services without cost sharing (such as copayment, coinsurance, or deductible), as soon as 12 months after a recommendation appears in any of the following sources:
- A and B rated recommendations of the United States Preventive Services Task Force (USPSTF);
- Immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention;
- For infants, children, and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA); and,
- For women, preventive care and screenings provided for in comprehensive guidelines supported by HRSA.
- States, pursuant to federal regulation, that nothing in 2) above requires a plan or insurer that has a network of providers to provide benefits for the items or services described in 2) above that are delivered by an out-of-network provider; or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in 2) above that are delivered by an out-of-network provider.
Existing state law:
- Requires health plans to be regulated by the Department of Managed Health Care (DMHC) and health insurers to be regulated by the California Department of Insurance (CDI).
- Mandates coverage for all generally accepted cancer screening tests, subject to all terms and conditions that apply, and screening for breast cancer, cervical cancer, mammography, and prostate cancer. Requires coverage for breast cancer diagnosis and treatment. Establishes requirements for mastectomies and lymph node dissections. Limits copayments on orally administered anticancer medications, as specified, until January 1, 2019. Mandates coverage for routine patient care costs related to clinical trials for an enrollee or insured diagnosed with cancer, as specified.
This bill:
- Requires every health plan contract and health insurance policy, except a specialized health plan contract or health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the USPSTF for individuals at average risk. Requires if an enrollee is at high risk for colorectal cancer, the plan or insurer to include additional colorectal cancer screening examinations as listed by the USPSTF as recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
- Prohibits, for an enrollee who is between 50 and 75 years of age, a health plan contract or insurance policy from imposing cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
- The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure; or,
- The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the USPSTF.
- States that nothing in this bill requires a plan or insurer that has a network of providers to provide benefits for items or services described in this bill that are delivered by an out-of-network provider or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
Comments
- Author’s statement. According to the author, stool blood tests are an important colorectal cancer screening option. Availability is better than for colonoscopy, the cost is lower, and they offer the opportunity to increase the overall screening rate which would reduce incidence and mortality. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy. Some prefer a stool blood test because the procedure is simpler, there is lower risk of complications and it is less invasive. Screening with stool blood tests has been shown to decrease incidence and mortality in randomized controlled trials, and years of life saved are essentially the same as with colonoscopy screening. However, the benefits of stool blood tests as a strategy to reach more Californians, especially in communities with lower access to colonoscopy services are not realized when there is a cost to patients. A co-pay or cost-sharing can be a barrier, preventing some individuals with positive stool blood tests from getting a follow up colonoscopy to complete the colorectal cancer screening process, defeating the purpose of screening. A policy that removes the cost to patients will make stool blood tests a more viable screening option and will reduce costs to payers.
- ACA Preventive services mandate. The ACA requires coverage for and elimination of cost-sharing on certain recommended preventive health services, for policies renewing on or after September 23, 2010, based on guidelines from the USPSTF. There are 15 covered preventive services for adults which include one-time screening for abdominal aortic aneurysm, screening and counseling for alcohol misuse, aspirin, blood pressure screening, cholesterol screening, depression screening, screening for Type 2 Diabetes, diet counseling, HIV screening, immunizations, obesity screening and counseling, prevention counseling for sexually transmitted infection, screening and cessation interventions for tobacco use, and colorectal cancer screening for adults over 50.
- Colorectal cancer screening. According to the National Cancer Institute, colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal cancer is the second leading cause of death from cancer in the United States. For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years. A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer. About 3% to 10% of the population has a first-degree relative with colorectal cancer. Male sex and black race are also associated with higher colorectal cancer incidence and mortality. Black adults have the highest incidence and mortality rates compared with other racial/ethnic subgroups. The final USPSTF recommendation for colorectal cancer screening recommends screening with one of several approved methodologies for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. The screening modalities and intervals are fecal occult blood test (FOBT), which has received an A or B recommendation from the USPSTF and Fecal immunochemical test, which is recommended in the 2016 draft updated guidelines. Both tests are suggested annually to detect cancer. A flexible sigmoidoscopy is recommended every five years to detect polyps and cancer and has received an A or B recommendation from the USPSTF. A colonoscopy is recommended every 10 years to detect polyps and cancer and has received an A or B recommendation. It is also recommended that a colonoscopy should be performed if test results are positive.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requested the University of California assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed an earlier version of this bill and issued an updated letter based on the April 27, 2016 version of this bill. Key findings include that there is a preponderance of evidence that USPSTF-recommended colorectal cancer screening modalities are medically effective for the detection and prevention of colorectal cancer screenings among average and high-risk individuals. For average-risk individuals, evidence exists suggesting a small but positive impact of insurance coverage for colorectal cancer screening and utilization (Cokkinides, 2011), and that low socioeconomic status individuals may benefit from the elimination of barriers to screening utilization (Fedewa, 2015a). CHBRP projects no measurable public health impact on the diagnosis or prevention of colorectal cancer at the population level due to the small number of enrollees who would avail themselves of the additional screening.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- No fiscal impact on the Medi-Cal program is anticipated, as program beneficiaries are not subject to cost sharing.
- Increased costs of $1.3 million per year to the California Public Employees’ Retirement System (CalPERS), due to increased utilization of screening tests (various funds). According to an analysis of a prior version of this bill by CHBRP, prohibiting cost sharing for specified screening will modestly increase utilization of screening examinations. Overall, CHBRP projects that about 2,500 additional individuals per year will receive colorectal screening exams due to the elimination of cost sharing. The proportional impact of that increased utilization on the CalPERS system is $1.3 million. According to CHBRP, subsequent amendments to the bill since that analysis was prepared will not substantially change the projected costs.
- No state cost to subsidize health care coverage through Covered California is anticipated. Under federal law, any new mandated health benefit that exceeds the benefits in the state’s essential health benefits benchmark plan would be a state responsibility. In other words, to the extent that the state imposes a new benefit mandate that exceeds the essential health benefits benchmark, the state would be responsible for paying for the cost to subsidize that benefit for those individuals who receive subsidized coverage through Covered California. Because this bill does not mandate a new benefit, but only change the terms of an existing benefit, the bill is not expected to result in the state being responsible for subsidizing coverage.
- One-time costs of about $90,000 over the first two years and ongoing costs of $25,000 per year for reviews of insurance plan compliance by CDI (Insurance Fund).
- Ongoing costs of less than $50,000 per year for review of health plan compliance by DMHC (Managed Care Fund).
American Cancer Society Cancer Action Network (co-source)
California Colorectal Cancer Coalition (co-source)
American College of Gastroenterology
American College of Surgeons
American Gastroenterology Association
American Society for Gastrointestinal Endoscopy
Association of Northern California Oncologists
Bayer
California Academy of Physician Assistants
California Academy of Preventive Medicine
California Black Health Network
California Chapters of the American College of Physicians
California Immigrant Policy Center
California Life Sciences Association
California Primary Care Association
Fresno Center for New Americans
Fresno Interdenominational Refugee Ministries
Health Officers Association of California
Medical Oncology Association of Southern California
Southeast Asia Resource Action Center
The Cambodian Family Community Center
Several individuals
OPPOSITION: (Verified 8/16/16)
America’s Health Insurance Plans
Blue Shield of California
California Association of Health Plans
California Chamber of Commerce
Department of Managed Health Care
ARGUMENTS IN SUPPORT: The American Cancer Society Action Network writes that colorectal cancer is the second leading cause of cancer deaths in the United States but is the most preventable with screening and early detection. Timely and appropriate screening can decrease colorectal cancer incidence and mortality by 30% to 60%. High-sensitivity FOBT tests are effective, non-invasive, easily accessible and safe screening tests that are more cost efficient than colonoscopies. However, a positive test result requires that a follow-up colonoscopy be provided. Multiple studies have shown that individuals are less likely to seek additional health services, including preventive screenings, when they are required to pay out-of-pocket. Additionally, research has shown that limiting colorectal cancer screening choices to only colonoscopy can result in a lower colorectal cancer screening completion rate compared to providing a choice between colonoscopy and a stool-based test, particularly among racial and ethnic minorities. The California Colorectal Cancer Coalition writes that many health insurers apply cost-sharing to colonoscopies that follow a positive stool blood test because they consider it a diagnostic procedure rather than a screening test. Patient cost can be more than $300 when a polyp or abnormal growth is removed during the screening colonoscopy. This charge is generally received unexpectedly after having a screening and can act as a disincentive for future screening for colon cancer. Finding an adenomatous polyp during a screening colonoscopy can be found in at least 50% of good quality colonoscopy exams. This bill eliminates this unexpected cost, and removes the financial disincentives, which prevent people from getting their colon cancer screening.
ARGUMENTS IN OPPOSITION: America’s Health Insurance Plans (AHIP) write that this bill creates a new mandate for health plans and insurers to cover costly services for diagnostic purposes without cost-sharing, which threatens the efforts of all health care stakeholders to provide consumers with meaningful health care choices and affordable coverage options. This bill will increase annual expenditures by $5.63 million for enrollees with DMHC-regulated plans and CDI-regulated policies. The state should be looking for ways to bring down health care costs for consumers, not drive them up. Extending the elimination of cost-sharing to diagnostic care in this instance creates a slippery slope to eliminating cost-sharing for other similar types of diagnostic care. As currently amended, this bill fails to follow the federal standard by not recognizing the value of in-network benefits – and results in increased costs in premiums if cost-sharing on out-of-network benefits was not permitted. A recent study conducted by AHIP found that in California the average billed charge for colonoscopies and biopsies was 252.7% of the Medicare rate. Requiring plans to cover such services and pay full billed charges would allow those providers to set charges at any level that they wish. According to DMHC, this bill imposes a zero cost sharing requirement on colorectal cancer services above and beyond the zero cost-sharing mandate for preventive services under the Affordable Care Act. This type of disease specific statute creates disparities and inequities for individuals that suffer from other diseases.
ASSEMBLY FLOOR: 67-5, 6/2/16
AYES: Achadjian, Alejo, Arambula, Atkins, Baker, Bloom, Bonilla, Bonta, Brown, Burke, Calderon, Campos, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Daly, Dodd, Eggman, Frazier, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, McCarty, Medina, Mullin, Nazarian, O'Donnell, Olsen, Quirk, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Weber, Wilk, Williams, Wood, Rendon
NOES: Travis Allen, Brough, Melendez, Obernolte, Patterson
NO VOTE RECORDED: Bigelow, Chang, Dahle, Beth Gaines, Gallagher, Kim, Mayes, Waldron
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/16/16 13:00:08
**** END ****
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1763 |
THIRD READING
Bill No: AB 1763
Amended: 6/27/16 in Senate
SENATE HEALTH COMMITTEE: 7-1, 6/22/16
AYES: Hernandez, Hall, Mitchell, Monning, Pan, Roth, Wolk
NOES: Nielsen
NO VOTE RECORDED: Nguyen
SENATE APPROPRIATIONS COMMITTEE: 5-2, 8/11/16
AYES: Lara, Beall, Hill, McGuire, Mendoza
NOES: Bates, Nielsen
ASSEMBLY FLOOR: 67-5, 6/2/16 - See last page for vote
SUBJECT: Health care coverage: colorectal cancer: screening and testing
SOURCE: American Cancer Society Cancer Action Network
California Colorectal Cancer Coalition
DIGEST: This bill requires health plan and health insurance coverage without cost sharing for specified colorectal cancer screening examinations and laboratory tests for individuals at average risk, and requires coverage for additional colorectal cancer screening examinations without cost-sharing for individuals at high risk, as specified. Prohibits the imposition of cost sharing on colonoscopies, including the removal of polyps, for an enrollee who is between 50 and 75 years of age and has received a positive test, as specified.
Existing federal law:
- Requires, pursuant to the Affordable Care Act (ACA), coverage of 10 essential health benefits and places limits on cost sharing.
- Requires, pursuant to Section 2713 of the Public Health Services Act, as added by the ACA, the preventive services without cost sharing (such as copayment, coinsurance, or deductible), as soon as 12 months after a recommendation appears in any of the following sources:
- A and B rated recommendations of the United States Preventive Services Task Force (USPSTF);
- Immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention;
- For infants, children, and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA); and,
- For women, preventive care and screenings provided for in comprehensive guidelines supported by HRSA.
- States, pursuant to federal regulation, that nothing in 2) above requires a plan or insurer that has a network of providers to provide benefits for the items or services described in 2) above that are delivered by an out-of-network provider; or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in 2) above that are delivered by an out-of-network provider.
Existing state law:
- Requires health plans to be regulated by the Department of Managed Health Care (DMHC) and health insurers to be regulated by the California Department of Insurance (CDI).
- Mandates coverage for all generally accepted cancer screening tests, subject to all terms and conditions that apply, and screening for breast cancer, cervical cancer, mammography, and prostate cancer. Requires coverage for breast cancer diagnosis and treatment. Establishes requirements for mastectomies and lymph node dissections. Limits copayments on orally administered anticancer medications, as specified, until January 1, 2019. Mandates coverage for routine patient care costs related to clinical trials for an enrollee or insured diagnosed with cancer, as specified.
This bill:
- Requires every health plan contract and health insurance policy, except a specialized health plan contract or health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the USPSTF for individuals at average risk. Requires if an enrollee is at high risk for colorectal cancer, the plan or insurer to include additional colorectal cancer screening examinations as listed by the USPSTF as recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services for the Medicare program.
- Prohibits, for an enrollee who is between 50 and 75 years of age, a health plan contract or insurance policy from imposing cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
- The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure; or,
- The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the USPSTF.
- States that nothing in this bill requires a plan or insurer that has a network of providers to provide benefits for items or services described in this bill that are delivered by an out-of-network provider or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
Comments
- Author’s statement. According to the author, stool blood tests are an important colorectal cancer screening option. Availability is better than for colonoscopy, the cost is lower, and they offer the opportunity to increase the overall screening rate which would reduce incidence and mortality. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy. Some prefer a stool blood test because the procedure is simpler, there is lower risk of complications and it is less invasive. Screening with stool blood tests has been shown to decrease incidence and mortality in randomized controlled trials, and years of life saved are essentially the same as with colonoscopy screening. However, the benefits of stool blood tests as a strategy to reach more Californians, especially in communities with lower access to colonoscopy services are not realized when there is a cost to patients. A co-pay or cost-sharing can be a barrier, preventing some individuals with positive stool blood tests from getting a follow up colonoscopy to complete the colorectal cancer screening process, defeating the purpose of screening. A policy that removes the cost to patients will make stool blood tests a more viable screening option and will reduce costs to payers.
- ACA Preventive services mandate. The ACA requires coverage for and elimination of cost-sharing on certain recommended preventive health services, for policies renewing on or after September 23, 2010, based on guidelines from the USPSTF. There are 15 covered preventive services for adults which include one-time screening for abdominal aortic aneurysm, screening and counseling for alcohol misuse, aspirin, blood pressure screening, cholesterol screening, depression screening, screening for Type 2 Diabetes, diet counseling, HIV screening, immunizations, obesity screening and counseling, prevention counseling for sexually transmitted infection, screening and cessation interventions for tobacco use, and colorectal cancer screening for adults over 50.
- Colorectal cancer screening. According to the National Cancer Institute, colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal cancer is the second leading cause of death from cancer in the United States. For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years. A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer. About 3% to 10% of the population has a first-degree relative with colorectal cancer. Male sex and black race are also associated with higher colorectal cancer incidence and mortality. Black adults have the highest incidence and mortality rates compared with other racial/ethnic subgroups. The final USPSTF recommendation for colorectal cancer screening recommends screening with one of several approved methodologies for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. The screening modalities and intervals are fecal occult blood test (FOBT), which has received an A or B recommendation from the USPSTF and Fecal immunochemical test, which is recommended in the 2016 draft updated guidelines. Both tests are suggested annually to detect cancer. A flexible sigmoidoscopy is recommended every five years to detect polyps and cancer and has received an A or B recommendation from the USPSTF. A colonoscopy is recommended every 10 years to detect polyps and cancer and has received an A or B recommendation. It is also recommended that a colonoscopy should be performed if test results are positive.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requested the University of California assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed an earlier version of this bill and issued an updated letter based on the April 27, 2016 version of this bill. Key findings include that there is a preponderance of evidence that USPSTF-recommended colorectal cancer screening modalities are medically effective for the detection and prevention of colorectal cancer screenings among average and high-risk individuals. For average-risk individuals, evidence exists suggesting a small but positive impact of insurance coverage for colorectal cancer screening and utilization (Cokkinides, 2011), and that low socioeconomic status individuals may benefit from the elimination of barriers to screening utilization (Fedewa, 2015a). CHBRP projects no measurable public health impact on the diagnosis or prevention of colorectal cancer at the population level due to the small number of enrollees who would avail themselves of the additional screening.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- No fiscal impact on the Medi-Cal program is anticipated, as program beneficiaries are not subject to cost sharing.
- Increased costs of $1.3 million per year to the California Public Employees’ Retirement System (CalPERS), due to increased utilization of screening tests (various funds). According to an analysis of a prior version of this bill by CHBRP, prohibiting cost sharing for specified screening will modestly increase utilization of screening examinations. Overall, CHBRP projects that about 2,500 additional individuals per year will receive colorectal screening exams due to the elimination of cost sharing. The proportional impact of that increased utilization on the CalPERS system is $1.3 million. According to CHBRP, subsequent amendments to the bill since that analysis was prepared will not substantially change the projected costs.
- No state cost to subsidize health care coverage through Covered California is anticipated. Under federal law, any new mandated health benefit that exceeds the benefits in the state’s essential health benefits benchmark plan would be a state responsibility. In other words, to the extent that the state imposes a new benefit mandate that exceeds the essential health benefits benchmark, the state would be responsible for paying for the cost to subsidize that benefit for those individuals who receive subsidized coverage through Covered California. Because this bill does not mandate a new benefit, but only change the terms of an existing benefit, the bill is not expected to result in the state being responsible for subsidizing coverage.
- One-time costs of about $90,000 over the first two years and ongoing costs of $25,000 per year for reviews of insurance plan compliance by CDI (Insurance Fund).
- Ongoing costs of less than $50,000 per year for review of health plan compliance by DMHC (Managed Care Fund).
American Cancer Society Cancer Action Network (co-source)
California Colorectal Cancer Coalition (co-source)
American College of Gastroenterology
American College of Surgeons
American Gastroenterology Association
American Society for Gastrointestinal Endoscopy
Association of Northern California Oncologists
Bayer
California Academy of Preventive Medicine
California Academy of Physician Assistants
California Black Health Network
California Chapters of the American College of Physicians
California Immigrant Policy Center
California Life Sciences Association
California Primary Care Association
Fresno Center for New Americans
Fresno Interdenominational Refugee Ministries
Health Officers Association of California
Medical Oncology Association of Southern California
Southeast Asia Resource Action Center
The Cambodian Family Community Center
Several individuals
OPPOSITION: (Verified 8/11/16)
America’s Health Insurance Plans
Blue Shield of California
California Chamber of Commerce
Department of Managed Health Care
ARGUMENTS IN SUPPORT: The American Cancer Society Action Network writes that colorectal cancer is the second leading cause of cancer deaths in the United States but is the most preventable with screening and early detection. Timely and appropriate screening can decrease colorectal cancer incidence and mortality by 30% to 60%. High-sensitivity FOBT tests are effective, non-invasive, easily accessible and safe screening tests that are more cost efficient than colonoscopies. However, a positive test result requires that a follow-up colonoscopy be provided. Multiple studies have shown that individuals are less likely to seek additional health services, including preventive screenings, when they are required to pay out-of-pocket. Additionally, research has shown that limiting colorectal cancer screening choices to only colonoscopy can result in a lower colorectal cancer screening completion rate compared to providing a choice between colonoscopy and a stool-based test, particularly among racial and ethnic minorities. The California Colorectal Cancer Coalition writes that many health insurers apply cost-sharing to colonoscopies that follow a positive stool blood test because they consider it a diagnostic procedure rather than a screening test. Patient cost can be more than $300 when a polyp or abnormal growth is removed during the screening colonoscopy. This charge is generally received unexpectedly after having a screening and can act as a disincentive for future screening for colon cancer. Finding an adenomatous polyp during a screening colonoscopy can be found in at least 50% of good quality colonoscopy exams. This bill eliminates this unexpected cost, and removes the financial disincentives, which prevent people from getting their colon cancer screening.
ARGUMENTS IN OPPOSITION: America’s Health Insurance Plans (AHIP) write that this bill creates a new mandate for health plans and insurers to cover costly services for diagnostic purposes without cost-sharing, which threatens the efforts of all health care stakeholders to provide consumers with meaningful health care choices and affordable coverage options. This bill will increase annual expenditures by $5.63 million for enrollees with DMHC-regulated plans and CDI-regulated policies. The state should be looking for ways to bring down health care costs for consumers, not drive them up. Extending the elimination of cost-sharing to diagnostic care in this instance creates a slippery slope to eliminating cost-sharing for other similar types of diagnostic care. As currently amended, this bill fails to follow the federal standard by not recognizing the value of in-network benefits – and results in increased costs in premiums if cost-sharing on out-of-network benefits was not permitted. A recent study conducted by AHIP found that in California the average billed charge for colonoscopies and biopsies was 252.7% of the Medicare rate. Requiring plans to cover such services and pay full billed charges would allow those providers to set charges at any level that they wish. According to DMHC, this bill imposes a zero cost sharing requirement on colorectal cancer services above and beyond the zero cost-sharing mandate for preventive services under the Affordable Care Act. This type of disease specific statute creates disparities and inequities for individuals that suffer from other diseases.
ASSEMBLY FLOOR: 67-5, 6/2/16
AYES: Achadjian, Alejo, Arambula, Atkins, Baker, Bloom, Bonilla, Bonta, Brown, Burke, Calderon, Campos, Chau, Chávez, Chiu, Chu, Cooley, Cooper, Dababneh, Daly, Dodd, Eggman, Frazier, Cristina Garcia, Eduardo Garcia, Gatto, Gipson, Gomez, Gonzalez, Gordon, Gray, Grove, Hadley, Harper, Roger Hernández, Holden, Irwin, Jones, Jones-Sawyer, Lackey, Levine, Linder, Lopez, Low, Maienschein, Mathis, McCarty, Medina, Mullin, Nazarian, O'Donnell, Olsen, Quirk, Ridley-Thomas, Rodriguez, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Wagner, Weber, Wilk, Williams, Wood, Rendon
NOES: Travis Allen, Brough, Melendez, Obernolte, Patterson
NO VOTE RECORDED: Bigelow, Chang, Dahle, Beth Gaines, Gallagher, Kim, Mayes, Waldron
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/15/16 20:17:19
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Ricardo Lara, Chair
2015 - 2016 Regular Session
AB 1763 (Gipson) - Health care coverage: colorectal cancer: screening and testing
Version: June 27, 2016 | Policy Vote: HEALTH 7 - 1 |
Urgency: No | Mandate: Yes |
Hearing Date: August 1, 2016 | Consultant: Brendan McCarthy |
This bill meets the criteria for referral to the Suspense File.
Bill Summary:
AB 1763 would require health insurers and health plans to provide coverage for specified colorectal cancer screening examinations and laboratory tests with no cost sharing.
Fiscal Impact:
- No fiscal impact on the Medi-Cal program is anticipated, as program beneficiaries are not subject to cost sharing.
- Increased costs of $1.3 million per year to CalPERS, due to increased utilization of screening tests (various funds). According to an analysis of a prior version of this bill by the California Health Benefits Review Program, prohibiting cost sharing for specified screening will modestly increase utilization of screening examinations. Overall, the Program projects that about 2,500 additional individuals per year will receive colorectal screening exams due to the elimination of cost sharing. The proportional impact of that increased utilization on the CalPERS system is $1.3 million. According to the Program, subsequent amendments to the bill since that analysis was prepared will not substantially change the projected costs.
- No state cost to subsidize health care coverage through Covered California is anticipated. Under federal law, any new mandated health benefit that exceeds the benefits in the state’s essential health benefits benchmark plan would be a state responsibility. In other words, to the extent that the state imposes a new benefit mandate that exceeds the essential health benefits benchmark, the state would be responsible for paying for the cost to subsidize that benefit for those individuals who receive subsidized coverage through Covered California. Because this bill does not mandate a new benefit, but only change the terms of an existing benefit, the bill is not expected to result in the state being responsible for subsidizing coverage.
- One-time costs of about $90,000 over the first two years and ongoing costs of $25,000 per year for reviews of insurance plan compliance by the Department of Insurance (Insurance Fund).
- Ongoing costs of less than $50,000 per year for review of health plan compliance by the Department of Managed Health Care (Managed Care Fund).
Background:
Under current law, health insurers are regulated by the Department of Insurance and health plans are regulated by the Department of Managed Health Care.
Under current federal and state law, health insurers and health plans are required to provide coverage without cost sharing for certain preventative services. One category of covered preventative are those services that have been rated either “A” or “B” by the United States Preventive Services Task Force.
The United States Preventive Services Task Force has given an “A” rating to colorectal screening for individuals aged 50 to 75, including fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Draft recommendations for an update to the recommendations includes an “A” rating for fecal immunochemical test.
While current law requires all recommended screening to be covered without cost sharing, in some circumstances recommended screening tests are not currently being covered. For example, patients can receive a fecal occult blood test without any cost sharing. If the test comes back positive, current guidelines recommend a follow-up colonoscopy. However, some health insurers or health plans characterize the follow-up colonoscopy as a diagnostic test, rather than a screening test. In those cases, the patient may have a copayment or coinsurance requirement.
Proposed Law:
AB 1763 would require health insurers and health plans to provide coverage for specified colorectal cancer screening examinations and laboratory tests with no cost sharing.
Specific provisions of the bill would:
- Require every health insurance policy or health care service plant contract (except a specialized health care service plan) to provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of “A” or “B” by the United States Preventive Services Task Force for individuals at average risk;
- For enrollees at high risk for colorectal cancer, the bill would require coverage without cost sharing for additional colorectal cancer screening examinations listed by the United States Preventive Services Task Force, at the frequency required under Medicare;
- Impose the above requirements beginning on January 1, 2018;
- For an enrollee between 50 and 75 years of age, prohibit cost sharing for colonoscopies when the colonoscopy is a screening procedure not occasioned by a positive result from another test or when a colonoscopy has been scheduled due to a positive result from another test;
- Specify that the bill does not require a health insurer or health plan to provide coverage for services provided by an out-of-network provider or prohibit a health insurer or health plan from imposing cost sharing requirements for services provided by an out-of-network provider.
Staff Comments:
According to an analysis of a prior version of the bill by the California Health Benefits Program, there is a preponderance of evidence that recommended screening tests for colorectal cancer are medically effective for the detection and prevention of colorectal cancer. At the individual level, the bill is likely to result in health and quality of life improvements due to earlier identification of colorectal cancer when it is more treatable. At the population level, the Program did not find that the bill will result in measureable public health impacts, because a relatively small number of individuals would receive additional screening under the bill.
The only costs that may be incurred by a local agency relate to crimes and infractions. Under the California Constitution, such costs are not reimbursable by the state.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Ed Hernandez, O.D., Chair
BILL NO: AB 1763
AUTHOR: | Gipson | ||
VERSION: | May 31, 2016 | ||
HEARING DATE: | June 22, 2016 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: colorectal cancer: screening and testing
SUMMARY:
Requires health plan and health insurance coverage without cost sharing for specified colorectal cancer screening examinations and laboratory tests for individuals at average risk, and requires coverage for additional colorectal cancer screening examinations without cost-sharing for individuals at high risk, as specified. Prohibits the imposition of cost sharing on colonoscopies, including the removal of polyps, for an enrollee who is between 50 and 75 years of age and has received a positive test, as specified.
Existing federal law:
- Requires, pursuant to the Affordable Care Act (ACA), coverage of the following ten essential health benefits (EHBs) and places limits on cost sharing:
- Ambulatory patient services;
- Emergency services;
- Hospitalizations;
- Maternity and newborn care;
- Mental health and substance use disorder services, including behavioral health treatment;
- Prescription drugs;
- Rehabilitative and habilitative services and devices;
- Laboratory services;
- Preventive and wellness services and chronic disease management; and,
- Pediatric services, including oral and vision care.
- Requires, pursuant to Section 2713 of the Public Health Services Act (PHSA) as added by the ACA the preventive services without cost sharing (such as copayment, coinsurance, or deductible), as soon as 12 months after a recommendation appears in any of following sources:
- A and B rated recommendations of the United States Preventive Services Task Force (USPSTF);
- Immunizations recommended by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention;
- For infants, children, and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration (HRSA); and,
- For women, preventive care and screenings provided for in comprehensive guidelines supported by HRSA.
- States, pursuant to federal regulation, that nothing in 2) above requires a plan or insurer that has a network of providers to provide benefits for the items or services described in 2) above that are delivered by an out-of-network provider; or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in 2) above that are delivered by an out-of-network provider.
Existing law:
- Requires health plans to be regulated by the Department of Managed Health Care (DMHC) and health insurers to be regulated by the California Department of Insurance (CDI).
- Mandates ten federally required EHBs, state mandated benefits and benefits covered under the Kaiser Small Group health plan, which is California’s EHB benchmark plan for non-grandfathered individual and small group health plan contracts and insurance policies, required under the ACA.
- Requires, to the extent required by federal law, a group or individual health care service plan contract or health insurance policy issued, amended, renewed, or delivered on or after September 23, 2010, to comply with Section 2713 of the PHSA as added by the ACA, and any rules or regulations issued under that section.
- Mandates coverage for all generally accepted cancer screening tests, subject to all terms and conditions that apply, and screening for breast cancer, cervical cancer, mammography, and prostate cancer. Requires coverage for breast cancer diagnosis and treatment. Establishes requirements for mastectomies and lymph node dissections. Limits copayments on orally administered anticancer medications, as specified, until January 1, 2019. Mandates coverage for routine patient care costs related to clinical trials for an enrollee or insured diagnosed with cancer, as specified.
This bill:
- Requires every health plan contract and health insurance policy, except a specialized health plan contract or health insurance policy, that is issued, amended, or renewed on or after January 1, 2018, to provide coverage without any cost sharing for all colorectal cancer screening examinations and laboratory tests assigned either a grade of A or a grade of B by the USPSTF for individuals at average risk. Requires if an enrollee is at high risk for colorectal cancer, the plan or insurer to include additional colorectal cancer screening examinations as listed by the USPSTF as recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services (CMS) for the Medicare program.
- Prohibits, for an enrollee who is between 50 and 75 years of age, a health plan contract or insurance policy from imposing cost sharing on colonoscopies, including the removal of polyps, when either of the following applies:
- The colonoscopy is a screening procedure not occasioned by a recent positive test or procedure; or,
- The colonoscopy has been scheduled because of a positive result on a test or procedure, other than a colonoscopy, assigned either a grade of A or a grade of B by the USPSTF.
FISCAL EFFECT: According to the Assembly Appropriations Committee, this bill has been narrowed since the California Health Benefits Review Program (CHBRP) reviewed its provisions. CHBRP found the following costs associated with a more expansive version of this bill:
- No costs to Medi-Cal (General Fund/federal) and $1.3 million to CalPERS for increased premiums;
- Increased employer-funded premium costs in the private insurance market of approximately $17.3 million; and,
- Increased premium expenditures by employees and individuals purchasing insurance of $26.5 million, and decreased out-of-pocket expenses of $35.4 million.
Though a revised CHBRP review is not available at this time, the narrower bill is likely to result in a lower cost impact than noted above.
Minor costs to CDI (Insurance Fund) and DMHC (Managed Care Fund) to verify plans and insurers comply with this requirement.
PRIOR VOTES:
Assembly Floor: | 65 - 4 |
Assembly Appropriations Committee: | 14 - 3 |
Assembly Health Committee: | 14 - 0 |
COMMENTS:
- Author’s statement. According to the author, stool blood tests are an important colorectal cancer screening option. Availability is better than for colonoscopy, the cost is lower, and they offer the opportunity to increase the overall screening rate which would reduce incidence and mortality. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy. Some prefer a stool blood test because the procedure is simpler, there is lower risk of complications and it is less invasive. Screening with stool blood tests has been shown to decrease incidence and mortality in randomized controlled trials, and years of life saved are essentially the same as with colonoscopy screening. However, the benefits of stool blood tests as a strategy to reach more Californians, especially in communities with lower access to colonoscopy services are not realized when there is a cost to patients. A co-pay or cost-sharing can be a barrier, preventing some individuals with positive stool blood tests from getting a follow up colonoscopy to complete the colorectal cancer screening process, defeating the purpose of screening. A policy that removes the cost to patients will make stool blood tests a more viable screening option and will reduce costs to payers.
- ACA Preventive services mandate. The ACA requires coverage for and elimination of cost-sharing on certain recommended preventive health services, for policies renewing on or after September 23, 2010, based on guidelines from the USPSTF. There are 15 covered preventive services for adults which include one-time screening for abdominal aortic aneurysm, screening and counseling for alcohol misuse, aspirin, blood pressure screening, cholesterol screening, depression screening, screening for Type 2 Diabetes, diet counseling, HIV screening, immunizations, obesity screening and counseling, prevention counseling for sexually transmitted infection, screening and cessation interventions for tobacco use, and colorectal cancer screening for adults over 50.
- Colorectal cancer screening. According to the National Cancer Institute, colorectal cancer is a disease in which malignant (cancer) cells form in the tissues of the colon or the rectum. Colorectal cancer is the second leading cause of death from cancer in the United States. For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years. A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer. About 3% to 10% of the population has a first-degree relative with colorectal cancer. Male sex and black race are also associated with higher colorectal cancer incidence and mortality. Black adults have the highest incidence and mortality rates compared with other racial/ethnic subgroups. The final USPSTF recommendation for colorectal cancer screening recommends screening with one of several approved methodologies for colorectal cancer starting at age 50 years and continuing until age 75 years. The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. The screening modalities and intervals are fecal occult blood test (FOBT), which has received an A or B recommendation from the USPSTF and Fecal immunochemical test (FIT), which is recommended in the 2016 draft updated guidelines. Both tests are suggested annually to detect cancer. A flexible sigmoidoscopy is recommended every five years to detect polyps and cancer and has received an A or B recommendation from the USPSTF. A colonoscopy is recommended every 10 years to detect polyps and cancer and has received an A or B recommendation. It is also recommended that a colonoscopy should be performed if test results are positive.
- Medicare recommendations. Medicare Part B (Medical Insurance) covers several types of colorectal cancer screening tests to help find precancerous growths or find cancer early, when treatment is most effective. Regarding cost-sharing, Medicare recommends patients find out how much the specific test, item, or service will cost, and indicates that the specific amount owed may depend on several things, like other insurance, how much the doctor charges, whether the doctor accepts assignment, the type of facility, and the location. The doctor or other health care provider may recommend services more often than Medicare covers. Or, they may recommend services that Medicare does not cover. If this happens, the patient may have to pay some or all of the costs. For colonoscopies, Medicare covers this test once every 24 months if the patient is at high-risk for colorectal cancer. If the patient is not at high-risk for colorectal cancer, Medicare covers this test once every 120 months, or 48 months after a previous flexible sigmoidoscopy.
- CHBRP analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002), requests the University of California assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed an earlier version of this bill and issued an updated letter based on the April 27, 2016 version of this bill. Key findings include:
- Coverage impacts and enrollees covered. Californians with state-regulated coverage impacted by this bill would increase from 13.8 million to 14.7 million. It is estimated that the percentage of enrollees 50 and older with coverage for colorectal cancer screening services without cost sharing would increase from 78% to 100%.
- Essential health benefits. CHBRP indicates that this bill impacts the terms and conditions of coverage for colorectal cancer screenings and tests, but does not change coverage itself, and therefore does not exceed EHBs.
- Medical effectiveness. There is a preponderance of evidence that USPSTF-recommended colorectal cancer screening modalities are medically effective for the detection and prevention of colorectal cancer screenings among average and high-risk individuals. For average-risk individuals, evidence exists suggesting a small but positive impact of insurance coverage for colorectal cancer screening and utilization (Cokkinides, 2011), and that low socioeconomic status individuals may benefit from the elimination of barriers to screening utilization (Fedewa, 2015a).
- Utilization. CHBRP assumes that the overall utilization of colorectal cancer screening and lab tests is going to increase by 0.4% (2,499 users), which is mainly due to the increase in use among enrollees aged 50 and older after the removal of cost-sharing requirements.
- Impact on expenditures. CHBRP estimates that this bill would increase total net annual expenditures by $9.86 million or 0.006% for enrollees with DMHC-regulated plans and CDI-regulated policies. This is due to a $26.61 million increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, partially offset by a decrease in enrollee expenditures for previously non-covered benefits ($35.37 million).
- Public health. CHBRP projects no measurable public health impact on the diagnosis or prevention of colorectal cancer at the population level due to the small number of enrollees who would avail themselves of the additional screening.
- Support. The American Cancer Society Action Network writes that colorectal cancer is the second leading cause of cancer deaths in the United States but is the most preventable with screening and early detection. Timely and appropriate screening can decrease colorectal cancer incidence and mortality by 30% to 60%. High-sensitivity FOBT tests are effective, non-invasive, easily accessible and safe screening tests that are more cost efficient than colonoscopies. However, a positive test result requires that a follow-up colonoscopy be provided. Multiple studies have shown that individuals are less likely to seek additional health services, including preventive screenings, when they are required to pay out-of-pocket. Additionally, research has shown that limiting colorectal cancer screening choices to only colonoscopy can result in a lower colorectal cancer screening completion rate compared to providing a choice between colonoscopy and a stool-based test, particularly among racial and ethnic minorities.
The California Colorectal Cancer Coalition (C4) writes that many health insurers apply cost-sharing to colonoscopies that follow a positive stool blood test because they consider it a diagnostic procedure rather than a screening test. Patient cost can be more than $300 when a polyp or abnormal growth is removed during the screening colonoscopy. This charge is generally received unexpectedly after having a screening and can act as a disincentive for future screening for colon cancer. Finding an adenomatous polyp during a screening colonoscopy can be found in at least 50% of good quality colonoscopy exams. This bill would eliminate this unexpected cost, and remove the financial disincentives, which prevent people from getting their colon cancer screening.
- Opposition. America’s Health Insurance Plans write that this bill creates a new mandate for health plans and insurers to cover costly services for diagnostic purposes without cost-sharing, which threatens the efforts of all health care stakeholders to provide consumers with meaningful health care choices and affordable coverage options. This bill will increase annual expenditures by $5.63 million for enrollees with DMHC-regulated plans and CDI-regulated policies. The state should be looking for ways to bring down health care costs for consumers, not drive them up. Extending the elimination of cost-sharing to diagnostic care in this instance creates a slippery slope to eliminating cost-sharing for other similar types of diagnostic care. As currently amended, this bill fails to follow the federal standard by not recognizing the value of in-network benefits – and would result in increased costs in premiums if cost-sharing on out-of-network benefits was not permitted. A recent study conducted by AHIP found that in California average billed charge for colonoscopies and biopsies was 252.7% of the Medicare rate. Requiring plans to cover such services and pay full billed charges would allow those providers to set charges at any level that they wish.
- Policy Comment. A tenet of closed network managed care is a requirement that enrollees use network providers for non-emergency services. This bill is silent on the extent to which this coverage without cost-sharing applies only when the tests or services are provided by in-network providers. The committee may wish to request an amendment to clarify this issue.
- Suggested Amendment. Add subdivision (c) Nothing in this section requires a plan or insurer that has a network of providers to provide benefits for items or services described in this section that are delivered by an out-of-network provider; or precludes a plan or insurer that has a network of providers from imposing cost-sharing requirements for the items or services described in this section that are delivered by an out-of-network provider.
SUPPORT AND OPPOSITION:
Support: California Colorectal Cancer Coalition (sponsor)
American Cancer Society Cancer Action Network (sponsor)
California Colorectal Cancer Coalition (cosponsor)
American College of Gastroenterology
American College of Surgeons
American Gastroenterology Association
American Society for Gastrointestinal Endoscopy
Bayer
California Academy of Physician Assistants
California Black Health Network
California Chapters of the American College of Physicians
California Immigrant Policy Center
California Life Sciences Association
California Primary Care Association
Fresno Center for New Americans
Fresno Interdenominational Refugee Ministries
Health Officers Association of California
Southeast Asia Resource Action Center
Several Individuals
Oppose: America’s Health Insurance Plans
Blue Shield of California (prior version)
California Chamber of Commerce (prior version)
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1763
Author:(Gipson)
As Amended Ver:May 31, 2016
Majority vote
Committee | Votes | Ayes | Noes |
Health | 14-0 | Wood, Maienschein, Bonilla, Burke, Campos, Chiu, Gomez, Roger Hernández, Lackey, Nazarian, Olsen, Rodriguez, Santiago, Steinorth | |
Appropriations | 14-3 | Gonzalez, Bloom, Bonilla, Bonta, Calderon, Daly, Eggman, Eduardo Garcia, Roger Hernández, Holden, Quirk, Santiago, Weber, Wood | Bigelow, Jones, Wagner |
SUMMARY: Requires health care service plan (health plan) contracts and health insurance policies to cover all colorectal cancer (CRC) screening examinations and laboratory tests assigned either an "A" or "B" grade by the United States Preventive Services Task Force (USPSTF) for individuals at average risk. Requires coverage for high risk individuals to include additional tests as listed by the USPSTF as a recommended screening strategy and at least at the frequency established pursuant to regulations issued by the federal Centers for Medicare and Medicaid Services. Prohibits cost sharing for individuals 50 to 75 years of age, as specified.
FISCAL EFFECT:
- This bill has been narrowed since the California Health Benefits Review Program (CHBRP) reviewed its provisions. CHBRP found the following costs associated with a more expansive version of this bill:
- No costs to Medi-Cal (General Fund/federal) and $1.3 million to CalPERS for increased premiums.
- Increased employer-funded premium costs in the private insurance market of approximately $17.3 million.
- Increased premium expenditures by employees and individuals purchasing insurance of $26.5 million, and decreased out-of-pocket expenses of $35.4 million.
Though a revised CHBRP review is not available at this time, the narrower bill is likely to result in a lower cost impact than noted above.
- Minor costs to the California Department of Insurance (Insurance Fund) and the Department of Managed Health Care (Managed Care Fund) to verify plans and insurers comply with this requirement.
COMMENTS: According to the author, this bill is needed to remove cost barriers to colonoscopies for adults 50 to 75 years of age, helping to catch cases of CRC sooner and save the lives of many. The author notes that the Patient Protection and Affordable Care Act (ACA) requires coverage of CRC screening tests by health plans with no cost sharing for persons age 50 to 75 years. This is important because cost had been a barrier to more people getting life-saving early detection tests for CRC. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy or may prefer a stool blood test because the procedure is simpler, has lower risk of complications, and is less invasive. If a stool blood test is positive, follow up colonoscopy is needed to examine the entire colon and remove any polyps found during the procedure. This process is still part of the "screening" and completes the continuum of care in CRC screening. However, some plans impose cost sharing for the follow up colonoscopy and/or the polyp removal. Some patients, because of cost, will forgo the follow up colonoscopy leaving them at higher risk for CRC and death. As with all cancers, the sooner it is detected and treated, the more likely the patient is to survive.
The USPSTF recommends, with an "A" grade, screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years. The federal Departments of Labor, Health and Human Services, and Treasury has published frequently asked questions (FAQs) with answers related to provisions of the ACA. Set 12 of these FAQs include the following two that are relevant to this bill:
Question: If a colonoscopy is scheduled and performed as a screening procedure pursuant to the USPSTF recommendation, is it permissible for a plan or issuer to impose cost-sharing for the cost of a polyp removal during the colonoscopy? Answer: No. Based on clinical practice and comments received from the American College of Gastroenterology, American Gastroenterological Association, American Society of Gastrointestinal Endoscopy, and the Society for Gastroenterology Nurses and Associates, polyp removal is an integral part of a colonoscopy. Accordingly, the plan or issuer may not impose cost-sharing with respect to a polyp removal during a colonoscopy performed as a screening procedure. On the other hand, a plan or issuer may impose cost-sharing for a treatment that is not a recommended preventive service, even if the treatment results from a recommended preventive service.
Question: Some USPSTF recommendations apply to certain populations identified as high-risk. Some individuals, for example, are at increased risk for certain diseases because they have a family or personal history of the disease. It is not clear, however, how a plan or issuer would identify individuals who belong to a high-risk population. How can a plan or issuer determine when a service should or should not be covered without cost-sharing? Answer: Identification of "high-risk" individuals is determined by clinical expertise. Decisions regarding whether an individual is part of a high-risk population, and should therefore receive a specific preventive item or service identified for those at high-risk, should be made by the attending provider. Therefore, if the attending provider determines that a patient belongs to a high-risk population and a USPSTF recommendation applies to that high-risk population, that service is required to be covered in accordance with the requirements of the interim final regulations (that is, without cost-sharing, subject to reasonable medical management).
The American Cancer Society Cancer Acton Network (ACS CAN), a cosponsor of this bill, states that CRC is the second leading cause of cancer deaths in the United States (U.S.) but is the most preventable with screening and early detection. Timely and appropriate screening can decrease CRC incidence and mortality by 30% to 60%. ACS CAN argues that the overall reduction of CRC incidence and mortality rates in the U.S. over the last few years has largely been attributed to increased preventative screening. Eliminating out-of-pocket cost – sharing for follow-up colonoscopy after a positive stool test will remove a significant barrier to CRC screening and it will greatly contribute to the goal of increasing the nation's CRC screening rate to 80% by 2018. The California Black Health Network supports this bill because of the devastating incidence of CRC in the African-American community.
The California Association of Health Plans argues that this bill will increase costs for employers and individuals by creating a new benefit mandate that expands CRC screening while prohibiting cost-sharing. Blue Shield of California argues that new USPSTF screening recommendations expected later in 2016 are likely to be different than current ones, making this bill premature. The Association of California Health Insurance Companies and America's Health Insurance Plans oppose all mandate bills this year arguing that they all negatively impact a robust health insurance marketplace offering competition and choice and stifle the use of innovative, evidence-based medicine. The California Chamber of Commerce has a number of concerns, including that the cost impact of this bill falls on all enrollees, not only those in the 50 to75-year age range.
Analysis Prepared by: John Gilman / HEALTH / (916) 319-2097 FN: 0003275
Date of Hearing: May 4, 2016
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 1763
Author:(Gipson) – As Introduced Ver:February 3, 2016
Policy Committee: | Health | Vote: | 14 - 0 |
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires health plans and insurers to cover, without cost-sharing, certain colorectal cancer screening procedures, under specified conditions. Specifically, this bill:
- Mirrors federal requirements requiring coverage without cost-sharing for colorectal cancer screening and laboratory exams assigned either a grade of A or B by the United States Preventive Services Task Force (USPSTF) for persons of average risk.
- Requires coverage for additional colorectal cancer screening examinations and laboratory tests as recommended by a health care provider, if a person is at high risk of colorectal cancer as determined by a health care provider.
- Specifies for an enrollee 50 years of age or older that colonoscopy, including the removal of polyps, is covered without cost-sharing when the colonoscopy is either: (1) a screening procedure not occasioned by a recent positive test or procedure, or (2) scheduled because of a positive result on a test or a procedure, other than colonoscopy, that has been assigned either a grade of A or B by the USPSTF.
FISCAL EFFECT:
- According to the California Health Benefits Review Program (CHBRP):
- No costs to Medi-Cal (GF/federal) and $1.3 million to CalPERS for increased premiums.
- Increased employer-funded premium costs in the private insurance market of approximately $17.3 million.
- Increased premium expenditures by employees and individuals purchasing insurance of $26.5 million, and decreased out-of-pocket expenses of $35.4 million.
- Minor costs to the California Department of Insurance (Insurance Fund) and the Department of Managed Health Care (Managed Care Fund) to verify plans and insurers comply with this requirement.
COMMENTS:
- Purpose. According to the author, this bill will remove cost barriers to colonoscopies for adults over 50 years of age, helping to catch cases of colorectal cancer earlier and improving survival.
- Background. Colon cancer is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together, they're often referred to as colorectal cancer. Most cases begin as small, noncancerous clumps of cells called adenomatous polyps, which may produce few, if any, symptoms. Over time some of these polyps become cancerous. For this reason, doctors recommend regular screening tests to help prevent colorectal cancer by identifying and removing polyps before they become cancerous.
- Current requirements. The federal Affordable Care Act requires coverage of certain preventive services that meet evidentiary standards without cost-sharing. Specifically, services given an "A" or "B" grade by the USPSTF, a federally designated body that reviews clinical evidence, are covered with no cost-sharing. The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years. This is given an "A" grade for this age group, meaning the USPSTF recommends the service and there is high certainty that the net benefit is substantial. They note the risks and benefits of these screening methods vary. The most recent recommendations were published in 2008, and they are in the final stages of being updated this year. There is no "A" or "B" grade recommendation for screening in individuals older than 75, neither in the current recommendation nor the new draft recommendation.
Colonoscopy, sigmoidoscopy, and blood tests are recommended screening modalities. A colonoscopy is recommended every 10 years beginning at age 50. It is the most comprehensive test and removes any offending polyps during the test. Fecal occult blood testing, another recommended screening modality, is performed annually. Blood testing may lead to greater compliance with recommended screening than colonoscopy, which is more invasive. A positive blood test can, however, provide an indication for a follow-up colonoscopy.
This bill is intended to address a situation where a follow-up colonoscopy is considered "diagnostic" and subject to a patient share of cost, versus a preventive screening which is covered with no share of cost. A colonoscopy following a positive blood test is recommended. However, the blood test is considered a highly sensitive test for colon cancer, meaning the follow-up colonoscopy may be considered a diagnostic test and therefore could, depending on the specifications of coverage and how a provider bills for it, be subject to cost-sharing. This bill also allows providers wide discretion to recommend other tests for individuals at high risk, and requires the tests be covered with no cost-sharing.
- CHBRP findings. CHBRP assumed an additional 2,500 screenings would occur as a result of this bill's requirements, but CHBRP projects no measurable public health impact at the population level due to the small number of additional enrollees who would avail themselves of screening. CHBRP states it is reasonable to assume that this reduction in financial burden would promote greater adherence to physician-recommended screenings on a long-term basis among this small set of people impacted.
- Essential Health Benefits (EHBs). Federal law requires the state to defray additional costs caused by any state mandates that exceed a set of federally defined EHBs. CHBRP states his bill impacts the terms and conditions of coverage for screenings and tests, but does not change coverage itself and thus does not exceed EHBs. Plans and insurers question this finding, as noted in their opposition, below.
- Support. This bill is sponsored by the American Cancer Society Cancer Acton Network and the California Colorectal Cancer Coalition, and it is supported by a number of other groups. Supporters indicate this bill will increase screening and survival as well as reduce racial, ethnic, and socioeconomic disparities by removing financial barriers to screening.
- Opposition. Health plans and insurers oppose this bill, citing increased costs and the potential to exceed EHBs. Blue Shield of California (BSC) argues that new USPSTF screening recommendations expected later in 2016 are likely to be different than current ones, making this bill premature. BSC is also concerned with this bill's requirement to cover, at no share of cost, a broad array of additional screenings and tests recommended by a physician if a person is considered "high risk."
- Staff Comments. This bill shifts costs of recommended screening tests fully to insurance coverage, reducing out-of-pocket expenses for colonoscopy and, for high-risk individuals, other tests as recommended. There is some survival benefit of an additional number of people getting tests because of the reduction in share of costs. For follow-up colonoscopies, this is generally beneficial and recommended testing and would likely benefit people who have higher cost-sharing and who would be more likely to skip the test if they had to pay out of pocket for it. Less is known about a net benefit of the additional screening tests for high-risk individuals, since that provision is broad, subject to interpretation by the provider, and not based on a finding from a nationally recognized entity. Health plans also believe this could exceed EHBs, resulting in a state fiscal impact to defray costs. It is unclear whether this bill exceeds EHBs, as it is unclear which cancer screening tests for people of high risk for cancer would be denied coverage under current law.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 19, 2016
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1763
Author:(Gipson) – As Introduced Ver:February 3, 2016
SUBJECT: Health care coverage: colorectal cancer: screening and testing.
SUMMARY: Requires health care service plan (health plan) contracts and health insurance policies to cover all colorectal cancer (CRC) screening examinations and laboratory tests assigned either an “A” or “B” grade by the United States Preventive Services Task Force (USPSTF) for individuals at average risk. Requires coverage for high risk individuals to include additional tests as recommended by the treating physician. Prohibits cost sharing for individuals 50 years of age or older. Specifically, this bill:
- Requires a health plan contract or health insurance policy renewed on or after January 1, 2018, to provide coverage for all CRC screening examinations and laboratory tests assigned either a grade of A or B by USPSTF for individuals at average risk. Requires the coverage to include, at a minimum, all of the following:
- High sensitivity fecal occult blood tests (FOBT);
- Flexible sigmoidoscopy with high sensitivity FOBT; and,
- Colonoscopies, including the removal of polyps during a screening procedure.
- High sensitivity fecal occult blood tests (FOBT);
- States that if an enrollee or insured is at high risk for CRC, the coverage required by 1) above must include additional CRC screening examinations and laboratory tests as recommended by the treating physician. States that an individual is at high risk for CRC if the individual has any of the following:
- A family medical history of CRC;
- A prior occurrence of cancer or precursor neoplastic polyp;
- A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohn’s disease, or ulcerative colitis; or,
- Other predisposing factors.
- A family medical history of CRC;
- Prohibits a health plan or health insurer from imposing cost sharing on an enrollee who is 50 years of age or older, for either of the following:
- The coverage required by this bill; or,
- Colonoscopies, including the removal of polyps during a screening procedure, if the enrollee has a positive result on any fecal test assigned either a grade of A or a grade of B by the USPSTF.
- The coverage required by this bill; or,
- Excludes from the requirement in 1) c) above high deductible health plans.
EXISTING LAW:
- Requires health plans to be regulated by the Department of Managed Health Care (DMHC) and health insurers to be regulated by the California Department of Insurance (CDI).
- Requires health plans and insurers providing health coverage in the individual and small group markets to cover, at a minimum, essential health benefits (EHBs), including the 10 EHB benefit categories in the Patient Protection and Affordable Care Act (ACA), and consistent with California’s EHB benchmark plan, the Kaiser Foundation Health Plan Small Group HMO 30 plan (Kaiser benchmark), as specified in state law.
- Requires issuers of individual and small group coverage to, at a minimum, cover EHBs in the following 10 categories: ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services, including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive and wellness services and chronic disease management, and pediatric services, including oral and vision care.
- Requires health plans to provide basic health care services, including physician services; hospital inpatient and ambulatory care services; diagnostic laboratory and diagnostic and therapeutic radiologic services; home health services; preventive health services; emergency health care services; and, hospice care.
- Requires, under the federal ACA, all non-grandfathered group health plans and health insurance coverage offered in the individual or group market to cover without cost sharing all evidenced-based items or services that have in effect a rating of “A” or “B” in the current recommendations of the USPSTF.
FISCAL EFFECT: This bill has not yet been heard by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, this bill is needed to remove cost barriers to colonoscopies for adults 50 to 75 years of age, helping to catch cases of CRC sooner and save the lives of many. The author notes that the ACA requires coverage of CRC screening tests by health plans with no cost sharing for persons age 50 to 75 years. This is important because cost had been a barrier to more people getting life-saving early detection tests for CRC. There are different types of CRC screenings; among the tests recommended by the USPSTF are stool blood tests such as the fecal immunochemical test (FIT) and the colonoscopy. Either test can be performed without copayments or cost sharing. The FIT test is a noninvasive, cost-effective stool blood test that is more acceptable than a colonoscopy to many people. Some individuals, including those from low income communities and communities of color may not have initial access to screening colonoscopy or may prefer a stool blood test because the procedure is simpler, has lower risk of complications, and is less invasive. If a FIT test is positive, follow up colonoscopy is needed to examine the entire colon and remove any polyps found during the procedure. This process is still part of the “screening” and completes the continuum of care in CRC screening. However, some plans impose cost sharing for the follow up colonoscopy and/or the polyp removal. Some patients, because of cost, will forgo the follow up colonoscopy leaving them at higher risk for CRC and death. As with all cancers, the sooner it is detected and treated, the more likely the patient is to survive.
- BACKGROUND. Colon cancer is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together, they're often referred to as CRC. Most cases of CRC begin as small, noncancerous (benign) clumps of cells called adenomatous polyps. Over time some of these polyps become CRCs. Polyps may be small and produce few, if any, symptoms. For this reason, doctors recommend regular screening tests to help prevent CRC by identifying and removing polyps before they become CRC. In most cases, it is not clear what causes CRC. Inherited gene mutations that significantly increase the risk of CRC can be passed through families, but these are linked to only a small percentage of CRCs. According to the Mayo Clinic, factors that may increase risk of CRC include:
- Older age. The great majority of people diagnosed with CRC are older than 50. CRC can occur in younger people, but it occurs much less frequently;
- African-American. African-Americans have a greater risk of CRC than do people of other races;
- A personal history of CRC or polyps. People who have already had CRC or adenomatous polyps, have a greater risk of CRC in the future;
- Inflammatory intestinal conditions. Chronic inflammatory diseases of the colon, such as ulcerative colitis and Crohn's disease, can increase your risk of CRC;
- Inherited syndromes that increase CRC risk. Genetic syndromes passed through generations of your family can increase your risk of CRC. These syndromes include familial adenomatous polyposis and hereditary nonpolyposis CRC, which is also known as Lynch syndrome;
- Family history of CRC. People are more likely to develop CRC if they have a parent, sibling or child with the disease. If more than one family member has CRC or rectal cancer, the risk is even greater;
- Low-fiber, high-fat diet. CRC and rectal cancer may be associated with a diet low in fiber and high in fat and calories. Research in this area has had mixed results. Some studies have also found an increased risk of CRC in people who eat diets high in red meat and processed meat;
- A sedentary lifestyle. People who are inactive are more likely to develop CRC. Getting regular physical activity may reduce the risk of CRC;
- Diabetes. People with diabetes and insulin resistance may have an increased risk of CRC;
- Obesity. People who are obese have an increased risk of CRC and an increased risk of dying of CRC when compared with people considered normal weight;
- Smoking. People who smoke may have an increased risk of CRC;
- Alcohol. Heavy use of alcohol may increase your risk of CRC; and,
- Radiation therapy for cancer. Radiation therapy directed at the abdomen to treat previous cancers may increase the risk of CRC.
- Older age. The great majority of people diagnosed with CRC are older than 50. CRC can occur in younger people, but it occurs much less frequently;
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, adds an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. Highlights of the CHBRP analysis on this bill as follows:
- Enrollees covered. CHBRP estimates that as of 2016, 25.2 million Californians have state-regulated coverage that would be subject to this bill. If enacted, CHBRP estimates the percentage of enrollees with coverage for CRC screening exams and lab tests assigned a grade of A or B by the USPSTF and additional screening and tests recommended by a physician would remain to be 100%. However, this bill would eliminate cost sharing on CRC screenings and lab tests for enrollees aged 50 and older including colonoscopies with the removal of polyps if the enrollee has a positive result on any fecal test. Since this bill does not apply to high-deductible plans, CHBRP estimates that 5% of enrollees aged 50 and older would be exempted from waving cost sharing. Accordingly, CHBRP estimates that the percent of enrollees aged 50 and older with coverage for CRC screening services listed in this bill without cost sharing would increase from 78% to 95%.
- Impact on expenditures. CHBRP estimates this bill would increase total net annual expenditures by $5.63 million or 0.004% for enrollees with DMHC regulated plans and CDI-regulated policies. This is due to a 25.92 million increase in total health insurance premiums paid by employers and enrollees for newly covered benefits, partially offset by a decrease in enrollee expenditures for previously noncovered benefits ($20.29 million). On a per member per month basis, CHBRP estimates that premiums on various plans and policies would increase by $0.003 to $0.21.
- EHBs. This bill impacts the terms and conditions of coverage for CRC screenings and tests, but does not change coverage itself. This bill does not exceed EHBs.
- Medical effectiveness. There is a preponderance of evidence that USPSTF-recommended CRC screening modalities are medically effective for the detection and prevention of CRC among average and high-risk individuals.
- Utilization. CHBRP assumes that the overall utilization of CRC screening and lab tests is going to increase by 0.3% (1,764 users), which is mainly due to the increase in use among enrollees aged 50 and older after the removal of cost-sharing requirements for CRC screening and lab tests.
- Public Health. CHBRP projects no measurable public health impact on the diagnosis or prevention of CRC at the population level due to the small number (1,764) of additional enrollees who would avail themselves of CRC screening. At the individual level, this bill would likely yield health and quality of life improvements, such as reduced screening-related financial burden and identification of CRC at earlier, and therefore more treatable, stages.
- Long-term impacts. To the extent that this bill would eliminate cost sharing for medically necessary additional CRC screenings and all events along the stepwise “continuum of screening,” including follow-up colonoscopies to positive fecal tests and polyp removal during colonoscopies, it would be reasonable to assume that this reduction in financial burden would promote greater adherence to physician-recommended screenings beyond those projected for the first 12 months following implementation of the mandate
- ACA Frequently Asked Questions (FAQs) RELATED TO THIS BILL. The federal Departments of Labor, Health and Human Services, and Treasury has published FAQs with answers related to provisions of the ACA. Set 12 of these FAQs include the following two that are relevant to this bill:
- Questions 5: If a colonoscopy is scheduled and performed as a screening procedure pursuant to the USPSTF recommendation, is it permissible for a plan or issuer to impose cost-sharing for the cost of a polyp removal during the colonoscopy?
No. Based on clinical practice and comments received from the American College of Gastroenterology, American Gastroenterological Association, American Society of Gastrointestinal Endoscopy, and the Society for Gastroenterology Nurses and Associates, polyp removal is an integral part of a colonoscopy. Accordingly, the plan or issuer may not impose cost-sharing with respect to a polyp removal during a colonoscopy performed as a screening procedure. On the other hand, a plan or issuer may impose cost-sharing for a treatment that is not a recommended preventive service, even if the treatment results from a recommended preventive service. - Question 7: Some USPSTF recommendations apply to certain populations identified as high-risk. Some individuals, for example, are at increased risk for certain diseases because they have a family or personal history of the disease. It is not clear, however, how a plan or issuer would identify individuals who belong to a high-risk population. How can a plan or issuer determine when a service should or should not be covered without cost-sharing?
- Questions 5: If a colonoscopy is scheduled and performed as a screening procedure pursuant to the USPSTF recommendation, is it permissible for a plan or issuer to impose cost-sharing for the cost of a polyp removal during the colonoscopy?
Identification of “high-risk” individuals is determined by clinical expertise. Decisions regarding whether an individual is part of a high-risk population, and should therefore receive a specific preventive item or service identified for those at high-risk, should be made by the attending provider. Therefore, if the attending provider determines that a patient belongs to a high-risk population and a USPSTF recommendation applies to that high-risk population, that service is required to be covered in accordance with the requirements of the interim final regulations (that is, without cost-sharing, subject to reasonable medical management).
- SUPPORT. The American Cancer Society Cancer Acton Network (ACS CAN), a cosponsor of this bill, states that CRC is the second leading cause of cancer deaths in the US but is the most preventable with screening and early detection. Timely and appropriate screening can decrease CRC incidence and mortality by 30% to 60%. ACS CAN argues that the overall reduction of CRC incidence and mortality rates in the U.S. over the last few years has largely been attributed to increased preventative screening. Eliminating out-of-pocket cost sharing for follow-up colonoscopy after a positive stool test will remove a significant barrier to CRC screening and it will greatly contribute to the goal of increasing the nation's CRC screening rate to 80% by 2018. The California Black Health Network supports this bill because of the devastating incidence of CRC in the African-American community. CRC is the third most common cancer in both black men and women with incidence rates higher in black males and females compared to whites (27% and 22% respectively). Research has shown that limiting CRC screening choices to only colonoscopy can result in a lower CRC screening completion rate compared to providing an initial choice between colonoscopy and a stool-based test, particularly among communities of color.
- OPPOSITION. The California Association of Health Plans argues that this bill will increase costs for employers and individuals by creating a new benefit mandate that expands CRC screening while prohibiting cost-sharing. Blue Shield of California (BSC) argues that new USPSTF screening recommendations expected later in 2016 are likely to be different than current ones, making this bill premature. BSC is also concerned with this bill's requirement to cover, at no share of cost, a broad array of additional screenings and tests recommended by a physician if a person is considered "high risk." Lastly, this bill is unclear in its intent to include secondary prevention. The Association of California Health Insurance Companies and America’s Health Insurance Plans oppose all mandate bills introduced this year because of possible state financial exposure, the need for a robust health insurance marketplace offering competition and choice, and the fact that mandates stifle the use of innovative, evidence-based medicine.
- OPPOSE UNLESS AMENDED. The California Chamber of Commerce has a number of concerns, including: a) this bill specifies coverage of certain screening tests that in the future may not meet USPSTF guidelines; b) this bill’s definition of high risk differs from the Medicare definition; and, c) the cost impact of this bill falls on all enrollees, not only those in the 50-75 year age range.
- PROPOSED AMENDMENTS. Amendments are proposed to clarify and narrow the scope of this bill, including:
- Delete the following language related to screening test coverage:
The coverage shall include, at a minimum, all of the following:
(1) High sensitivity fecal occult blood tests (FOBT).
(2) Flexible sigmoidoscopy with high sensitivity FOBT.
(3) Colonoscopies, including the removal of polyps during a screening procedure.
- Delete the following language related to high risk criteria:
For purposes of this subdivision, an individual is at high risk for colorectal cancer if the individual has any of the following:
(A) A family medical history of colorectal cancer.
(B) A prior occurrence of cancer or precursor neoplastic polyps.
(C) A prior occurrence of a chronic digestive disease condition, including, but not limited to, inflammatory bowel disease, Crohn’s disease, or ulcerative colitis.
(D) Other predisposing factors.
- Clarify provisions regarding colonoscopy and polyp removal without cost sharing; and,
- Other technical changes.
REGISTERED SUPPORT / OPPOSITION:
Support
American Cancer Society Cancer Acton Network (cosponsor)
California Colorectal Cancer Coalition (cosponsor)
American College of Gastroenterology
American College of Physicians
American College of Surgeons
American Gastrological Association
American Society for Gastrointestinal Endoscopy
California Primary Care Association
California Black Health Network
Opposition
America’s Health Insurance Plans
Association of California Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: John Gilman / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):